Faculty of Pharmaceutical, Biomedical and Veterinary Sciences. Pharmacy
Laboratory of Pharmaceutical Technology and Biopharmacy
Nature reviews drug discovery
8(2009):12, p. 929-930
University of Antwerp
In September 2009, telavancin (Vibativ; Theravance/Astellas Pharma), a lipoglycopeptide antibiotic, was approved by the US FDA for the treatment of adult patients with complicated skin and skin structure infections.